High Purity Orforglipron (LY3502970) Powder CAS 2212020-52-3 Oral GLP-1 Receptor Agonist Research Raw Material
TDS 28 Inquiries
2212020-52-3
Pharmaceutical Grade
99%
Xi'an
FULECARE
Double plastic bags plus aluminum foil bag
2027-12-29
Slu-pp-332,BAM 15
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionOrforglipron is an oral, non-peptide, small-molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company as a weight-loss drug. Currently, the drug is still in Phase III clinical trials and has not yet received approval from the U.S. Food and Drug Administration (FDA). Eli Lilly's CEO expects the FDA to approve its investigational oral weight-loss drug, orforglipron, by March 2026, and to submit an application for the treatment of type 2 diabetes by the end of 2026.Research & Reference Note
High Purity Orforglipron (LY3502970) Powder CAS 2212020-52-3 Oral GLP-1 Receptor Agonist Research Raw Material is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Authoritative sourcesDisclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals
CertificatesBasic Info-
Product Name:
Orforglipron
Other Name:1,2,4-Oxadiazol-5(2H)-one, 3-[(1S,2S)-1-[2-[[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2,3-dihydro-2-oxo-1H-imidazol-1-yl]-2,4,6,7-tetrahydro-4-methyl-5H-pyrazolo[4,3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcy...;LY3502970;GLP-1 receptor agonist 1 USP/EP/BP;Orforglipron;Orforglipron（LY3502970）;LY3502970 (Orforglipron);3-((1S,2S)-1-(5-((S)-2,2-dimethyltetrahydro-2H-pyran-4-yl)-2-((S)-3-(3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)-2-(4-fluoro-3,5-dimethylphenyl)-4-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine-5-carbonyl)-1H-indol-1-yl)-2-methylcyclopropyl)-1,2,4-oxadiazol-5(4H)-one;OWL 833
CAS No.:2212020-52-3
Molecular Formula:C48H48F2N10O5
InChIKeys:USUWIEBBBWHKNI-BBGRWQLENA-N
Molecular Weight:882.97
EC Number:278-636-5
Color/Form:Off-white to light yellow
Categories:
Characteristics-
Density:
1.50±0.1 g/cm3(Predicted)
PKA:7.33±0.20(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Slu-pp-332,BAM 15
-
Location:
No. 11608, 16th Floor, Unit 1, Building 1, West of Zhangba Liu Road, South Third Ring Road, High tech Zone, Xi'an City, Shaanxi Province
-
Payment Terms:
L/C,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
335
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Inquiry History28 Inquiries
Country Product Purchase Quantity Date Posted 
Bulgaria
orforglipron
1 KG Aug 27, 2025 
Austria
Orforglipron
1000 MT Jun 12, 2026 
Switzerland
Orforglipron
10 MG Apr 25, 2026 
United States
Orforglipron
20 G Apr 3, 2026
United States
Orforglipron
10 G Mar 29, 2026
United States
oforglipron
3 KG Jul 4, 2025 
United Kingdom
Orforglipron
1 G Jul 9, 2026 
Belgium
Orforglipron
1 G Jun 14, 2026 
Puerto Rico
Orforglipron
1 G Mar 2, 2026
United States
Orforglipron
10 G Oct 24, 2025
United States
Orforglipron
1 G Sep 30, 2025
United States
Orforglipron
1 G Sep 26, 2025
United States
Orforglipron
1 G Sep 26, 2025
United States
orforglipron
1 MT Sep 20, 2025
United States
Orforglipron
1 KG Apr 18, 2025 
Canada
LY-3502970
10 G Feb 26, 2026 
India
orforglipron
1.00 G Jul 16, 2026
United States
Orforglipron
200 PCS Jun 18, 2026
United States
orforglipron
10 G Apr 20, 2026
United States
Orforglipron
10 G Apr 6, 2026 Post an enquiry for this product
